The Biden administration is rescinding ex-President Trump's unimplemented most favored nation drug pricing rule, which was disliked by 340B entities and drug manufacturers.
Biden Axing Trump’s “Most Favored Nation” Drug Pricing Rule that 340B Entities and Pharma Both Disliked
The Biden administration is rescinding an unimplemented Trump-era regulation that would have pegged Medicare Part B drug reimbursement for 50 expensive, physician-administered drugs on the lowest price that drug manufacturers provide in similar countries.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.